Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The DNA-directed RNA polymerase beta subunit (encoded by rpoB) is an essential bacterial enzyme responsible for catalyzing the transcription of DNA into RNA. Rifampicin exerts its antibacterial activity by binding to the beta subunit of bacterial RNA polymerase, specifically in the DNA/RNA channel. This binding blocks RNA chain elongation after the initiation step, preventing the synthesis of bacterial proteins crucial for survival. Resistance to rifampicin typically emerges through mutations in the rpoB gene, particularly in the rifampicin resistance-determining region, which reduce drug binding affinity. Rifampicin does not affect mammalian RNA polymerase, contributing to its selectivity for bacterial pathogens.
Inhibits bacterial DNA-dependent RNA polymerase by binding to its beta subunit, blocking RNA chain elongation and thus impeding bacterial RNA and protein synthesis (steric-occlusion mechanism)
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA-directed RNA polymerase beta subunit (bacterial) (RNA polymerase β subunit).